NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-MH-19-425 from the NIH Guide for Grants and Contracts. The National Institute of Mental Health (NIMH), in collaboration with the Office of the Global AIDS Coordinator (OGAC) is soliciting revision applications for implementation science research that will inform delivery and scale-up of pre-exposure prophylaxis (PrEP) at PEPFAR sites.
Limited Competition: NeuroImaging Tools and Resources Collaboratory (R24 Clinical Trial Not Allowed)
Funding Opportunity RFA-EB-18-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.
Notice NOT-OD-19-044 from the NIH Guide for Grants and Contracts
Notice NOT-HS-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-011 from the NIH Guide for Grants and Contracts
Notice NOT-HS-19-005 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-114 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites qualified research institution to seek funds to modernize existing research facilities that focus on HIV/AIDS-related research. Institutions that support non-human primate colonies are encouraged to apply to update the animal housing infrastructure and research-dedicated space needed for the animal-related research efforts. Any request must be justified by the needs of NIH-funded investigators who used the laboratory space or rely on the animals raised and care for by the facilities. Applications for regular upkeep and repairs are not appropriate for this FOA.
Notice NOT-AI-19-020 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-008 from the NIH Guide for Grants and Contracts
Notice NOT-ES-19-005 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-053 from the NIH Guide for Grants and Contracts
Notice NOT-AI-19-018 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-112 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).
Funding Opportunity PA-19-111 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).
Funding Opportunity PAR-19-113 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.
Funding Opportunity PAS-19-105 from the NIH Guide for Grants and Contracts. The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?e?a?d?i?n?g? ?e?d?g?e? of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.
Funding Opportunity RFA-DK-18-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites new and renewal applications to participate in the Consortium on Modeling Autoimmune Interactions (CMAI). CMAI is a component of the Human Islet Research Network (HIRN) that is focused on developing robust systems to measure and model the biology of human type 1 diabetes. Projects will explore and validate research models designed to advance pre-clinical scientific discovery, mechanistic dissection of disease processes, and testing of potential interventions for T1D.
Notice NOT-AR-19-033 from the NIH Guide for Grants and Contracts
Notice NOT-HS-19-004 from the NIH Guide for Grants and Contracts
Notice NOT-DA-18-048 from the NIH Guide for Grants and Contracts